Analysis reveals IFI44 as a prognostic biomarker in glioma, suggesting its role in immune regulation and tumor aggressiveness.
IFI44 may drive glioma progression through dual mechanisms of immune microenvironment remodeling and promotion of tumor cell aggressiveness, supporting its potential as a prognostic biomarker and therapeutic target. Although preliminary knockdown and overexpression assays were performed, the underlying mechanisms of IFI44-mediated immune regulation and tumor progression require further investigation.
No takes yet. Share an insight, caveat, or question.
Erhu Yan (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: